Get startedLog in
    Picture of ExpreS2ion Biotech Holding AB logo

    EXPRS2 — ExpreS2ion Biotech Holding AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Expres2ion Biotech Holding Provides Update On Its Novel Breast Cancer Vaccine Candidate Es2b-C001

    Picture of ExpreS2ion Biotech Holding AB logoExpreS2ion Biotech Holding AB
    08/02/2022 13:18
    Feb 8 (Reuters) - ExpreS2ion Biotech Holding AB  EXPRS2.ST :
    * PROVIDES AN UPDATE ON ITS NOVEL BREAST CANCER VACCINE
CANDIDATE
ES2B-C001
    * PLANS TO CONDUCT AN ADDITIONAL PRECLINICAL SAFETY STUDY IN
FIRST
HALF OF 2023
    * IS NOW AIMING TO FILE CLINICAL TRIAL APPLICATION FOR PHASE
I
TRIAL IN SECOND HALF OF 2023
    * AIMS AT DOSING FIRST IN HUMAN IN FIRST HALF OF 2024

Source text for Eikon:  ID:nWkrc3wpkw 
Further company coverage:  EXPRS2.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on ExpreS2ion Biotech Holding AB

    See all news